Cited by 258Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchMultiple Sclerosis Research Studies

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Open access

Laubach, J, Garderet, L, Mahindra, A, Gahrton, G, Caers, J, Sezer, O, Voorhees, P, Leleu, X, Johnsen, H E, Streetly, M, Jurczyszyn, A, Ludwig, H, Mellqvist, U-H, Chng, W-J, Pilarski, L, Einsele, H, Hou, J, Turesson, I, Zamagni, E, Chim, C S, Mazumder, A, Westin, J, Lu, J, Reiman, T, Kristinsson, S, Joshua, D, Roussel, M, O'Gorman, P, Terpos, E, McCarthy, P, Dimopoulos, M, Moreau, P, Orlowski, R Z, Miguel, J S, Anderson, K C, Palumbo, A, Kumar, S, Rajkumar, V, Durie, B, Richardson, P G·2016·Leukemia

DOI 10.1038/leu.2015.356

Open this paper in CoChat — free account Open PDF

Abstract

The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.

Integrity signals

Registry

Crossref · 10.1038/leu.2015.356

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citation
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Self-citation
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citation
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citation
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Self-citation
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citation
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Cavo, M., Tacchetti, P., Patriarca, F. F., Petrucci, M. T., Pantani, L., Galli, M., Raimondo, F. D., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 823
Self-citation
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Self-citation
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Miguel, J. F. S., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 801
Self-citation
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J. R., Siegel, D. S. D., Irwin, D. H., Richardson, P. G. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 726
Self-citation
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 695
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 664
Self-citation
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A. G., Miguel, J. F. S., Robak, T., Dmoszyńska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 644
Self-citation
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Harousseau, J., Attal, M., Avet‐Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T. T. F., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 540
Self-citation
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Barlogie, B., Desikan, R. K., Eddlemon, P., Spencer, T., Zeldis, J. B., Munshi, N. C., Badros, A. Z., Zangari, M., Anaissie, E. J., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 539
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citation
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Self-citation
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B. E., Hegenbart, U., Somlo, G., Chauncey, T. R., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2955 · Cited by 403
Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Gahrton, G., Tura, S., Ljungman, P. T., Bélanger, C., Brandt, L., Cavo, M., Facon, T. T. F., Grañena, A., Gore, M. E., Gratwohl, A. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251802 · Cited by 377
Self-citation
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
Rajkumar, S. V., Rosiñol, L., Hussein, M. A., Catalano, J. V., Wiktor-Jędrzejczak, W., Lucy, L. M., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
Schey, S., Fields, P. A., Bartlett, J. B., Clarke, I., Ashan, G., Knight, R., Streetly, M. J., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 312
Self-citation
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Cavo, M., Pantani, L., Petrucci, M. T., Patriarca, F. F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A. P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408898 · Cited by 311
Self-citation
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Lonial, S., Vij, R., Harousseau, J., Facon, T. T. F., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X. P., Tsao, L. C., Westland, C. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Self-citation
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Richardson, P. G. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M. M. H., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481325 · Cited by 291
Self-citation
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., Rosa, L. D., Pregno, P., Grasso, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7172 · Cited by 268
Self-citation
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Vij, R., Wang, M. L., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., Kukreti, V., Jagannath, S., McDonagh, K. T., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-03-414359 · Cited by 256
Self-citation
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
Ocio, E. M., Richardson, P. G. G., Rajkumar, S. V., Palumbo, A. P., Mateos, M., Orlowski, R. Z., Kumar, S. K., Usmani, S. Z., Roodman, D., Niesvizky, R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 239
Self-citation
A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
Glasmacher, A. G., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld‐Toal, M., Orlopp, K. S., Schmidt‐Wolf, I. G. H., & Gorschlüter, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05914.x · Cited by 237
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Dimopoulos, M. A., Siegel, D. S. D., Lonial, S., Qi, J., Hájek, R., Facon, T. T. F., Rosiñol, L., Williams, C. D., Blacklock, H. A., Goldschmidt, H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70398-x · Cited by 231
Self-citation
Plasma Cell Neoplasms
McKenna, R. W., & Linden, M. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-10918-3 · Cited by 194
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D. W., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4918 · Cited by 188
Self-citation
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Reece, D. E., Song, K., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C. I., Masih‐Khan, E., Trieu, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193458 · Cited by 183
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
Björkstrand, B., Iacobelli, S., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Musto, P., Beksaç, M., Bosi, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7312 · Cited by 182
Self-citation
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Crawley, C. R., Iacobelli, S., Björkstrand, B., Apperley, J. F., Niederwieser, D. W., Gahrton, G., & for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2006) · Blood · doi:10.1182/blood-2006-07-036848 · Cited by 180
Self-citation
DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma
Lee, C., Barlogie, B., Munshi, N. C., Zangari, M., Fassas, A., Jacobson, J. L., van Rhee, F., Cottler‐Fox, M., Muwalla, F., & Tricot, G. J. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Jagannath, S., Richardson, P. G. G., Barlogie, B., Berenson, J. R., Singhal, S., Irwin, D. H., Srkalović, G., Schenkein, D. P., Esseltine, D. L., & Anderson, K. C. (2006) · PubMed · Cited by 162
Self-citation
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Richardson, P. G. G., Siegel, D. S. D., Baz, R., Kelley, S. L., Munshi, N. C., Laubach, J. P., Sullivan, D. M., Alsina, M., Schlossman, R. L., Ghobrial, I. M., et al. (2012) · Blood · doi:10.1182/blood-2012-08-450742 · Cited by 162
Self-citation
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162
Self-citation
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Richardson, P. G. G., Jagannath, S., Hussein, M. A., Berenson, J. R., Singhal, S., Irwin, D. H., WILLIAMS, S. F., Bensinger, W., Badros, A. Z., Vescio, R. A., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196238 · Cited by 159
Self-citation
New Drugs for Myeloma
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 158
Self-citation
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
Dimopoulos, M. A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., Poziopoulos, C., Xilouri, I., Zorzou, M. P., Anagnostopoulos, N. I., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200326 · Cited by 144
Self-citation
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
Avet‐Loiseau, H., Soulier, J., Fermand, J., Yakoub‐Agha, I., Attal, M., Hulin, C., Garderet, L., Belhadj, K., Dorvaux, V., Minvielle, S., et al. (2010) · Leukemia · doi:10.1038/leu.2009.273 · Cited by 138
Self-citation
Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
Kumar, S. K., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Geyer, S. M., Iturria, N. L., Fonseca, R., Hayman, S. R., Lust, J. A., Kyle, R. A., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.34 · Cited by 134
Self-citation
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Mileshkin, L. (2003) · Blood · doi:10.1182/blood-2002-09-2846 · Cited by 132
Adverse effects of thalidomide administration in patients with neoplastic diseases
Dimopoulos, M. A., & Eleutherakis-Papaiakovou, V. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.040 · Cited by 130
Self-citation
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Dimopoulos, M. A., Anagnostopoulos, A., & Weber, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.200 · Cited by 129
Self-citation
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
Wang, M. L., Martin, T. G., Bensinger, W., Alsina, M., Siegel, D. S. D., Kavalerchik, E., Huang, M., Orlowski, R. Z., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2013-07-511170 · Cited by 128
Self-citation
Treatment Options for Relapsed and Refractory Multiple Myeloma
Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 126
Self-citation
Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity
Richardson, P. G. G., Schlossman, R. L., Jagannath, S., Alsina, M., Desikan, R. K., Blood, E., Weller, E. A., Mitsiades, C. S., Hideshima, T., Davies, F. E., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.875 · Cited by 126
Self-citation
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
Palumbo, A., Gay, F., Bringhen, S., Falcone, A. P., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn018 · Cited by 123
Self-citation
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Richardson, P. G. G., Wolf, J., Jakubowiak, A. J., Zonder, J., Lonial, S., Irwin, D. H., Densmore, J. J., Krishnan, A. Y., Raje, N. S., Bar, M. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9788 · Cited by 121
Self-citation
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
Dimopoulos, M. A., Kastritis, E., Christoulas, D., Migkou, M., Gavriatopoulou, M., Gkotzamanidou, M. A., Iakovaki, M., Matsouka, C., Mparmparoussi, D., Ρούσσου, Μ., et al. (2010) · Leukemia · doi:10.1038/leu.2010.175 · Cited by 120
Self-citation
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Lentzsch, S., O'Sullivan, A., Kennedy, R. C., Abbas, M., Dai, L., Pregja, S. L., Burt, S., Boyiadzis, M. M., Roodman, G. D., Mapara, M. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395715 · Cited by 119
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Knop, S. T., Gerecke, C., Liebisch, P., Topp, M. S., Platzbecker, U., Sezer, O., Vollmuth, C., Falk, K., Glasmacher, A., Maeder, U., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184135 · Cited by 119
Self-citation
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N., Ackermann, J., Küenburg, E., Wieser, R., Zielinski, C. C., & Drach, J. W. (2006) · Leukemia · doi:10.1038/sj.leu.2404459 · Cited by 119
Self-citation
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Jimenez-Zepeda, V. H., Mikhael, J. R., Winter, A., Franke, N., Masih‐Khan, E., Trudel, S., Chen, C. I., Kukreti, V., & Reece, D. E. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.044 · Cited by 117
Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
Kyriakou, C. A., Thomson, K. J., D’Sa, S., Flory, A. J., Hanslip, J., Goldstone, A. H., & Yong, K. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05521.x · Cited by 115
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Mikhael, J. R., Belch, A. R., Prince, H. M., Lucio, M. N., Maiolino, Â., Corso, A., Petrucci, M. T., Musto, P., Komarnicki, M. A., & Stewart, A. K. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07409.x · Cited by 107
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients
Morgan, G. J., Schey, S., Wu, P., Srikanth, M., Phekoo, K. J., Jenner, M. W., & Davies, F. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06538.x · Cited by 102
Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
Reece, D. E., Rodriguez, G. P., Chen, C. I., Trudel, S., Kukreti, V., Mikhael, J. R., Pantoja, M. A., Xu, W., & Stewart, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2372 · Cited by 101
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
Ludwig, H., Kasparu, H., Leitgeb, C., Rauch, E., Linkesch, W., Zojer, N., Greil, R., Seebacher, A., Pour, L., Weißmann, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-521468 · Cited by 100
Self-citation
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
Olin, R. L., Vogl, D. T., Porter, D., Luger, S. M., Schuster, S. J., Tsai, D. E., Siegel, D. L., Cook, R. J., Mangan, P. A., Cunningham, K., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.334 · Cited by 99
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases
Rasche, L., Bernard, C., Topp, M. S., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H., & Knop, S. T. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1414-5 · Cited by 99
Self-citation
The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
Knop, S. T., Straka, C., Haen, M., Schwedes, R., Hebart, H. F., & Einsele, H. (2005) · PubMed · Cited by 95
Self-citation
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Niesvizky, R., Martin, T. G., Bensinger, W., Alsina, M., Siegel, D. S. D., Kunkel, L., Wong, A., Lee, S., Orlowski, R. Z., & Wang, M. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3352 · Cited by 82
Self-citation
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
Patriarca, F. F., Einsele, H., Spina, F., Bruno, B., Isola, M., Nozzoli, C., Nozza, A., Sperotto, A. A., Morabito, F., Stuhler, G., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.026 · Cited by 81
Self-citation
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
Lilienfeld‐Toal, M. V., Hahn‐Ast, C., Furkert, K., Hoffmann, F., Naumann, R., Bargou, R. C., Cook, G., & Glasmacher, A. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01121.x · Cited by 78
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
Jakubowiak, A. J., Siegel, D. S. D., Martin, T., Wang, M., Vij, R., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.152 · Cited by 77
Self-citation
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani, M., Corvatta, L., Marconi, M., Visani, G., Alesiani, F., Brunori, M., Galieni, P., Catarini, M., Burattini, M., Centurioni, R., et al. (2006) · PubMed · Cited by 77
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
Brioli, A., Giles, H. V., Pawlyn, C., Campbell, J. P., Kaiser, M., Melchor, L., Jackson, G. H., Gregory, W. M., Owen, R. G., Child, J. A., et al. (2014) · Blood · doi:10.1182/blood-2013-12-542662 · Cited by 76
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Harrison, S. J., Quach, H., Link, E. K., Seymour, J. F., Ritchie, D. S., Ruell, S. A., Dean, J., Januszewicz, H., Johnstone, R. W., Neeson, P. J., et al. (2011) · Blood · doi:10.1182/blood-2011-03-339879 · Cited by 76
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
Qazilbash, M. H., Saliba, R. M., Lima, M. J. G. D., Hosing, C. M., Couriel, D. R., Aleman, A., Roden, L., Champlin, R. E., & Giralt, S. (2006) · Cancer · doi:10.1002/cncr.21700 · Cited by 75
The role of second autografts in the management of myeloma at first relapse.
Alvares, C. L., Davies, F. E., Horton, C., Patel, G. W., Powles, R., & Morgan, G. J. (2006) · PubMed · Cited by 72
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Lemieux‐Blanchard, É., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.013 · Cited by 72
Self-citation
Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study
Plesner, T., Lokhorst, H. M., Gimsing, P., Nahi, H., Lisby, S., & Richardson, P. G. G. (2012) · Blood · doi:10.1182/blood.v120.21.73.73 · Cited by 70
Self-citation
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 68
Self-citation
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 67
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., di Toritto, T. C., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 62
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
Jakubowiak, A. J., Richardson, P. G. G., Zimmerman, T. M., Alsina, M., Kaufman, J. L., Kandarpa, M., Kraftson, S. J., Ross, C. W., Harvey, C., Hideshima, T., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09173.x · Cited by 62
Self-citation
BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity
Heffner, L. T., Jagannath, S., Zimmerman, T. M., Lee, K. P., Rosenblatt, J. M., Lonial, S., Lutz, R. J., Czeloth, N., Osterroth, F., Ruehle, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.4042.4042 · Cited by 62
Self-citation
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation
Kröger, N. M., Shimoni, A., Schilling, G., Schwerdtfeger, R., Bornhäuser, M., Nagler, A., Zander, A. R., Heinzelmann, M., Brand, R., Gahrton, G., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07984.x · Cited by 60
Self-citation
Autologous retransplantation for patients with recurrent multiple myeloma
Sellner, L., Heiß, C., Benner, A., Raab, M. S., Hillengaß, J., Hose, D., Lehners, N., Egerer, G., Ho, A. D., Goldschmidt, H., et al. (2013) · Cancer · doi:10.1002/cncr.28104 · Cited by 59
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
Tovar, N., de Larrea, C. F., Aróstegui, J. I., Cibeira, M. T., Rosiñol, L., Rovira, M., Elena, M. S., Filella, X., Yagüe, J., & Bladé, J. (2013) · Haematologica · doi:10.3324/haematol.2013.084350 · Cited by 55
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
Schey, S., Morgan, G. J., Ramasamy, K., Hazel, B., Ładoń, D., Corderoy, S., Jenner, M. W., Phekoo, K. J., Boyd, K. D., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08250.x · Cited by 55
D(T) PACE as salvage therapy for aggressive or refractory multiple myeloma
Gerrie, A. S., Mikhael, J. R., Cheng, L., Jiang, H., Kukreti, V., Panzarella, T., Reece, D. E., Stewart, K., Trieu, Y., Trudel, S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12325 · Cited by 53
An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma
Conner, T., Doan, Q. D., Walters, I. B., LeBlanc, A. L., & Beveridge, R. A. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.016 · Cited by 50
Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Weber, D. M., Graef, T. T., Hussein, M. A., Sobecks, R. M., Schiller, G. J., Lupinacci, L. C., Hardwick, J. S., & Jagannath, S. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.07.007 · Cited by 47
First thalidomide clinical trial in multiple myeloma: a decade
van Rhee, F., Dhodapkar, M. V., Shaughnessy, J. D., Anaissie, E. J., Siegel, D. S. D., Hoering, A., Zeldis, J. B., Jenkins, B., Singhal, S., Mehta, J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140954 · Cited by 44
Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland
Hrusovsky, I., Emmerich, B., von Rohr, A., Voegeli, J., Taverna, C., Olie, R. A., Pliskat, H., Frohn, C., & Hess, G. (2010) · Oncology · doi:10.1159/000322866 · Cited by 44
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
Damaj, G. L., Malard, F., Hulin, C., Caillot, D., Garidi, R., Royer, B., Marit, G., Stoppa, A., Baños, A., Morineau, N., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.622422 · Cited by 44
Self-citation
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Party, T. K. M. M. W., Kim, Y., Sohn, S., Lee, J.-H., Yang, D.-H., Moon, J., Ahn, J.-S., Kim, H., & Lee, J. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0856-x · Cited by 43
Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma
Shimoni, A., Hardan, I., Ayuk, F. A., Schilling, G., Atanackovic, D., Zeller, W., Yerushalmi, R., Zander, A. R., Kröger, N. M., & Nagler, A. (2010) · Cancer · doi:10.1002/cncr.25228 · Cited by 42
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
Palumbo, A. P., Larocca, A., Falco, P., Sanpaolo, G., Falcone, A. P., Federico, V., Canepa, L., Crugnola, M., Genuardi, M., Magarotto, V., et al. (2010) · Leukemia · doi:10.1038/leu.2010.58 · Cited by 41
Self-citation
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Dimopoulos, M. A., Beksaç, M., Benboubker, L., Roddie, H., Allietta, N., Broer, E., Couturier, C., Mazier, M., Angermund, R., & Facon, T. T. F. (2013) · Haematologica · doi:10.3324/haematol.2013.084376 · Cited by 39
Self-citation
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
Grover, J. K., Uppal, G., & Raina, V. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf258 · Cited by 38
Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Orlowski, R. Z., et al. (2013) · Blood · doi:10.1182/blood.v122.21.690.690 · Cited by 38
Self-citation
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea, M., Cagnetta, A., Gobbi, M., Patrone, F., Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2013) · PubMed · Cited by 37
Self-citation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
Efebera, Y. A., Qureshi, S., Cole, S., Saliba, R. M., Pelosini, M., Patel, R. M., Koca, E., Mendoza, F. L., Wang, M. L., Shah, J. J., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.015 · Cited by 36
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)
Venner, C. P., Connors, J. M., Sutherland, H. J., Shepherd, J. D., Hamata, L., Mourad, Y. A., Barnett, M. J., Broady, R. C., Forrest, D. L., Hogge, D. E., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.531409 · Cited by 35
New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Cea, M., Cagnetta, A., Gobbi, M., Patrone, F., Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581945 · Cited by 34
Self-citation
Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse
Papanikolaou, X. D., Repousis, P., Τζένου, Τ., Maltezas, D., Kotsopoulou, M., Megalakaki, K., Angelopoulou, M. K., Dimitrakoloulou, E., Koulieris, E., Bartzis, V., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.746683 · Cited by 33
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma
Offidani, M., Corvatta, L., Marconi, M., Olivieri, A., Catarini, M., Mele, A., Brunori, M., Candela, M., Malerba, L., Capelli, D., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200401 · Cited by 32
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077
Pönisch, W., Heyn, S., Beck, J., Wagner, I., Mohren, M., Hoffmann, F. A., Lange, T., Schmalfeld, M., Zehrfeld, T., Schwarzer, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12361 · Cited by 31
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up
Richardson, P. G. G., Jagannath, S., Jakubowiak, A. J., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Mazumder, A., Munshi, N. C., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3049.3049 · Cited by 30
Self-citation
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone‐refractory myeloma
van de Donk, N. W. C. J., Wittebol, S., Minnema, M. C., & Lokhorst, H. M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07931.x · Cited by 27
Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study
Raje, N. S., Hari, P., Vogl, D. T., Jagannath, S., Orlowski, R. Z., Supko, J. G., Stephenson, P. A., Jones, S. S., Wheeler, C., & Lonial, S. (2012) · Blood · doi:10.1182/blood.v120.21.4061.4061 · Cited by 26
Self-citation
The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study
Shah, J. J., Zonder, J. A., Cohen, A. D., Bensinger, W., Kaufman, J. L., Orlowski, R. Z., Harvey, R. D., Abidi, M. H., Thomas, S. K., Walker, D., et al. (2012) · Blood · doi:10.1182/blood.v120.21.449.449 · Cited by 26
Self-citation
Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens
ANAGNOSTOPOULOS, A., Hamilos, G., Zorzou, M. P., Grigoraki, V., Anagnostou, D., & Dimopoulos, M. A. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000151860 · Cited by 24
Self-citation
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Smetana, J., Beránková, K., Zaoralová, R., Němec, P., Grešlíková, H., Kupská, R., Mikulášová, A., Fröhlich, J., Ševčı́ková, S., Zahradova, L., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.11.012 · Cited by 23
Self-citation
Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)
Leleu, X. P., Karlin, L., Macro, M., Hulin, C., Garderet, L., Roussel, M., Arnulf, B., Pegourié, B., Kolb, B., Stoppa, A., et al. (2013) · Blood · doi:10.1182/blood.v122.21.689.689 · Cited by 18
Self-citation
Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Ahn, J., Jung, S., Yang, D., Bae, S.-Y., Kim, Y., Kim, H., & Lee, J. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.02.004 · Cited by 16
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
Chim, C. S., Lie, A. K. W., Chan, E. Y. T., Leung, Y.-H., Cheung, S., Chan, S. Y. T., Liang, R. H. S., & Kwong, Y. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0959-4 · Cited by 16
Self-citation
Daratumumab, a CD38 Monoclonal Antibody in Patients With Multiple Myeloma - Data From A Dose-Escalation Phase I/II Study
Plesner, T., Lokhorst, H. M., Gimsing, P., Nahi, H., Basse, L., Lisby, S., & Richardson, P. G. G. (2013) · University of Southern Denmark Research Portal (University of Southern Denmark) · Cited by 15
Self-citation
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients
Buda, G., Orciuolo, E., Galimberti, S., Ghio, F., & Petrini, M. (2013) · Blood · doi:10.1182/blood.v122.21.5377.5377 · Cited by 14
Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma
Raje, N. S., Faber, E. A., Richardson, P. G. G., Schiller, G. J., Hohl, R. J., Cohen, A. D., Forero, A., Carpenter, S. P., Cronier, D. M., Kaiser, C. J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.447.447 · Cited by 13
Self-citation
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
Baz, R., Martin, T. G., Alsina, M., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., Nardelli, L. A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.303.303 · Cited by 12
Self-citation
Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma
Richardson, P. G. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M. M. H., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood.v122.21.1970.1970 · Cited by 10
Self-citation
Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity
Kumar, S. K., LaPlant, B. R., Chng, W. J., Zonder, J. A., Callander, N. S., Roy, V., Furth, B., Erlichman, C., & Stewart, K. (2012) · Blood · doi:10.1182/blood.v120.21.76.76 · Cited by 9
Self-citation
Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial
Rodon, P., Hulin, C., Pegourié, B., Tiab, M., Anglaret, B., Benboubker, L., Jardel, H., Decaux, O., Kolb, B., Roussel, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.4044.4044 · Cited by 8
Self-citation
Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Shah, J. J., Orlowski, R. Z., Alexanian, R., Wang, M. L., Thomas, S. K., Qazilbash, M. H., Parmar, S., Shah, N. D., Bashir, Q., Popat, U., et al. (2010) · Blood · doi:10.1182/blood.v116.21.1948.1948 · Cited by 6
Self-citation
Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)
Nijhof, I. S., Zweegman, S., Levin, M., Koene, H. R., Beeker, A., Bloem, A. C., Bos, G. M. J., Faber, L. M., Klein, S. K., de Kruijf, E.-J. F. M., et al. (2013) · Blood · doi:10.1182/blood.v122.21.287.287 · Cited by 2

Sorted by citations

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 901
Self-citation
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Brudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., Hungria, V., Salwender, H. J., Suzuki, K., Kim, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30525-8 · Cited by 404
Self-citation
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Self-citation
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
“Lastly, immunomodulators like lenalidomide, pomalidomide, and thalidomide are frequently used in triplet or quadruplet induction regimens and maintenance regimens [33,34].”
Background

See all 258

Authors: Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., Jurczyszyn, A., Ludwig, H., Mellqvist, U.-H., Chng, W.-J., Pilarski, L., Einsele, H., Hou, J., Turesson, I., Zamagni, E., Chim, C. S., Mazumder, A., Westin, J., Lu, J., Reiman, T., Kristinsson, S., Joshua, D., Roussel, M., O'Gorman, P., Terpos, E., McCarthy, P., Dimopoulos, M., Moreau, P., Orlowski, R. Z., Miguel, J. S., Anderson, K. C., Palumbo, A., Kumar, S., Rajkumar, V, Durie, B., & Richardson, P. G.
Affiliations: Dana-Farber Cancer Institute (US)
Hôpital Saint-Antoine (FR)
University of California, San Francisco (US)
Karolinska University Hospital (SE)
Centre Hospitalier Universitaire de Liège (BE)
Istanbul Memorial Hospital (TR)
University of North Carolina at Chapel Hill (US)
Centre Hospitalier Universitaire de Lille (FR)
Aalborg University Hospital (DK)
King's College Hospital (GB)
Jagiellonian University (PL)
Wilhelminen Hospital (AT)
Sahlgrenska University Hospital (SE)
National University of Singapore (SG)
University of Alberta (CA)
Universitätsklinikum Würzburg (DE)
Second Military Medical University (CN)
Skåne University Hospital (SE)
University of Bologna (IT)
Queen Mary Hospital (CN)
NYU Langone Health (US)
Peking University People's Hospital (CN)
Dalhousie University (CA)
Royal Prince Alfred Hospital (AU)
Hôpital Purpan (FR)
National and Kapodistrian University of Athens (GR)
Roswell Park Comprehensive Cancer Center (US)
Nantes Université (FR)
The University of Texas MD Anderson Cancer Center (US)
University of Turin (IT)
Mayo Clinic (US)
Cedars-Sinai Medical Center (US)
Corresponding author: Richardson, P G
ORCID: Laubach, J
Garderet, L
Caers, J
Sezer, O
Voorhees, P
Leleu, X
Johnsen, H E
Streetly, M
Jurczyszyn, A
Ludwig, H
Einsele, H
Hou, J
Turesson, I
Zamagni, E
Chim, C S
Mazumder, A
Reiman, T
Kristinsson, S
Roussel, M
Terpos, E
McCarthy, P
Dimopoulos, M
Moreau, P
Orlowski, R Z
Anderson, K C
Palumbo, A
Kumar, S
Durie, B
Richardson, P G
Venue: Leukemia
Publisher: Springer Science and Business Media LLC
Published: 2015-12-29
Volume: 30
Issue: 5
Pages: 1005-1017
ISSN: 0887-6924 (ISSN-L)
1476-5551
DOI: 10.1038/leu.2015.356
OpenAlex: W2216303864
Cited by: 258
References: 133
Citations by year: 2026: 7 · 2025: 15 · 2024: 10 · 2023: 33 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 10
FWCI: 3.99
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Leukemia (publishedVersion)
PubMed (publishedVersion)
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Lund University Publications (Lund University) (submittedVersion)
ORBi (University of Liège) (submittedVersion)
VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords: relapsed multiple myeloma, relapsed/refractory multiple myeloma, second relapse, autologous stem cell transplantation, allogeneic stem cell transplantation, conventional-dose chemotherapy, diagnostic assessment, treatment selection
MeSH terms: Antineoplastic Agents, Humans, Multiple Myeloma, Recurrence, Salvage Therapy, Practice Guidelines as Topic, Hematopoietic Stem Cell Transplantation, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks